Premature ovarian failure and the FMR1 gene

Seminars in Reproductive Medicine

Volumn 18, Issue 1, 2000, Pages 59-66

  Murray, A ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

FMR1; Premature ovarian failure; Premutation

Indexed keywords

FRAGILE X MENTAL RETARDATION PROTEIN; RNA BINDING PROTEIN; UNCLASSIFIED DRUG;

DIZYGOTIC TWINS; FRAGILE X SYNDROME; GENE MUTATION; HETEROZYGOSITY; HUMAN; OVARY DISEASE; REVIEW;

EID: 0034481291     PISSN: 15268004     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-13476     Document Type: Review

References (83)

1. An investigation of the age at menopause
2. Incidence of premature ovarian failure
3. Inheritance in idiopathic premature ovarian failure: Analysis of 71 cases
4. Familial idiopathic premature ovarian failure: An overrated and underestimated genetic disease?
5. Structural anomalies of the X chromosome: Personal observation and review of non-mosaic cases
6. X-chromosome abnormalities in women with premature ovarian failure
7. Puberty and its disorders: Turner syndrome
8. Turner syndrome and female sex chromosome aberrations: Deduction of the principal factors involved in the development of clinical features
9. Analysis of Xq deletions
10. Molecular and cytogenetic studies of an X: Autosome translocation in a patient with premature ovarian failure and review of the literature
11. The critical region on the human Xq
12. Eleven X chromosome breakpoints associated with premature ovarian failure (POF) map to a 15-Mb YAC contig spanning Xq21
13. Mutation in the follicle-stimulating hormone receptor gene causes hereditary hypergonadotropic ovarian failure
14. A human homologue of the Drosophila melanogaster diaphanous gene is disrupted in a patient with premature ovarian failure: Evidence for conserved function in oogenesis and implications for human sterility
15. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome
16. Trinucleotide repeat expansion and human disease
17. Tissue specific expression of FMR-1 provides evidence for a functional role in fragile-X syndrome
18. FMRP is associated to the ribosomes via RNA
19. Fine structure of the human FMR1 gene
20. Simple tandem DNA repeats and human genetic disease
21. Population studies of the fragile(X): A molecular approach
22. Prenatal diagnosis and carrier screening for fragile X by PCR
23. Population screening at the FRAXA and FRAXE loci: Molecular analyses of boys with learning difficulties and their mothers
24. Direct diagnosis by DNA analysis of the fragile X syndrome of mental retardation
25. FRAXA and RAXE: The results of a five year survey
26. Fragile X syndrome and fragile XE mental retardation
27. Physical mapping across the fragile X: Hypermethylation and clinical expression of the fragile X syndrome
28. DNA methylation represses FMR-1 transcription in fragile X syndrome
29. Fragile X syndrome
30. Prevalence of fragile X syndrome
31. Screening for the fragile X syndrome among the mentally retarded: A clinical study
32. The fragile(X): A marker for the Martin-Bell syndrome
33. The marker(X) syndrome: A cytogenetic and genetic analysis
34. Further segregation analysis of the fragile X syndrome with special reference to transmitting males
35. Recurrence risks for relatives in families with an isolated case of the fragile X syndrome
36. The fragile X premutation in carriers and its effect on mutation size in offspring
37. Inheritance of the fragile X syndrome: Size of the fragile X premutation is a major determinant of the transition to full mutation
38. Molecular predictors of cognitive involvement in female carriers of fragile X syndrome
39. Molecular/clinical correlations in females with fragile X
40. Heterozygous fragile X female: Historical, physical, cognitive, and cytogenetic features
41. Obstetrical and gynecological complications in fragile X carriers: A multicenter study
42. Confirmation of early menopause in fragile X carriers
43. Fragile X premutation is a significant risk factor for premature ovarian failure: The International Collaborative POF in Fragile X study: Preliminary data
44. Premature ovarian failure (POF) in Brazilian fragile X carriers
45. Premature ovarian failure (POF) and fragile X premutation females: From POF to fragile X carrier identification, from fragile X carrier diagnosis to POF association data
46. Reproductive and menstrual history of females with fragile X expansions
47. Serum concentrations of follicle stimulating hormone may predict premature ovarian failure in FRAXA premutation women
48. Fragile X premutations in familial premature ovarian failure
49. Fragile X premutation screening in women with premature ovarian failure
50. Studies of FRAXA and FRAXE in women with premature ovarian failure
51. Association between idiopathic premature ovarian failure and fragile X premutation
52. Prevalence of carriers of premutation-size alleles of the FMR1 gene and implications for the population genetics of the fragile X syndrome
53. The high prevalence of fragile X premutation carrier females: Is this frequency unique to the French Canadian population?
54. Fragile X premutations are not a major cause of early menopause
55. FRAXA premutations are not a cause of familial premature ovarian failure
56. FMR1 repeat analysis in patients with ovarian dysfunction or failure
57. The frequency of twins: Maternal age and parity
58. Do mothers of dizygotic twins have earlier menopause: A role for fragile X?
59. The female and the fragile X: A study of 144 obligate female carriers
60. Dizygous twinning and premature menopause in fragile X syndrome
61. Twinning and premature ovarian failure in premutation fragile X carriers
62. Is fragile X syndrome a risk factor for dizygotic twinning?
63. Examination of factors that influence the expansion of the fragile X mutation in a sample of conceptuses from known carrier females
64. Investigation of the twinning rate in families with the fragile X syndrome
65. The X inactivation centre and X chromosome imprinting
66. Genetic control of X inactivation and processes leading to X-inactivation skewing
67. Tissue specificity of X-chromosome inactivation patterns
68. Imprinting effect in premature ovarian failure confined to paternally inherited fragile X premutations
69. Reply to the letters from Murray et al and Vianna-Morgante and Costa
70. No evidence for parent of origin influencing premature ovarian failure in fragile X premutation carriers
71. Premature ovarian failure is associated with maternally and paternally inherited premutation in Brazilian families with fragile X
72. Premature ovarian failure among fragile X premutation carriers: Parent-of-origin effect?
73. Fragile X premutations and (TA)n estrogen receptor polymorphism in women with ovarian dysfunction
74. Evidence of linkage disequilibrium between POF1 and FRAXAC1
75. Translational suppression by trinucleotide repeat expansion at FMR-1
76. Elevated levels of FMR1 mRNA in carrier males: A new mechanism of involvement in the fragile-X syndrome
77. Expansion of a CUG trinucleotide repeat in the 3' untranslated region of myotonic dystrophy protein kinase transcripts results in nuclear retention of transcripts
78. Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy
79. Triplet-repeat transcripts: A role for RNA in disease
80. Novel proteins with binding specificity for DNA CTG repeats and RNA CUG repeats: Implications for myotonic dystrophy
81. Human genetics '99: Trinucleotide repeats. Myotonic dystrophy: The role of RNA CUG triplet repeats
82. Enhanced expression of the murine Fmr1 gene during germ cell proliferation suggests a special function in both the male and the female gonad
83. Menstrual disorders and endocrine profiles in fragile X carriers prior to 40 years of age: A pilot study